Engineered COVID-19 Antibody Enables Extremely Rapid Identification of SARS-CoV-2 in Nasal Mucus, Saliva, and Blood
By LabMedica International staff writers Posted on 20 Oct 2020 |
Illustration
An engineered monoclonal antibody against the COVID-19 virus spike protein could enable extremely rapid identification of the SARS-CoV-2 virus in nasal mucus, saliva, and blood, as well as potentially allow for rapid identification of the virus present on surfaces, such as food, cell phones, door handles, etc., through testing only a small sample.
The new class of anti-spike protein monoclonal antibodies against COVID-19 was created by researchers at Halberd Corporation (Jackson Center, PA, USA) and Arizona State University (ASU Tempe, AZ, USA). Halberd has begun the process of filing the first of multiple planned joint patent applications for this new class of antibody and will not publicly disclose details concerning the rapid identification methodology until appropriate patent protections are in place. Halberd scientists believe that the breakthrough could help solve the COVID-19 pandemic by accelerating identification of the SARS-CoV-2 virus, and the scientific analysis of the effectiveness of COVID-19 therapeutics.
Scientists from Halberd believe that rapid identification is essential to permit effectively initiating therapeutics in the earliest phases of COVID-19. Early identification and treatment could substantially curtail the spread of COVID-19.
“The progress over the past month has been phenomenal and is already yielding patentable intellectual property. We foresee this as just the first of many potential patent applications to address the rapid detection, prevention, and treatment of COVID-19,” said Dr. Patricio Reyes, Chief Technical Officer of Halberd Corporation.
Related Links:
Arizona State University
Halberd Corporation
The new class of anti-spike protein monoclonal antibodies against COVID-19 was created by researchers at Halberd Corporation (Jackson Center, PA, USA) and Arizona State University (ASU Tempe, AZ, USA). Halberd has begun the process of filing the first of multiple planned joint patent applications for this new class of antibody and will not publicly disclose details concerning the rapid identification methodology until appropriate patent protections are in place. Halberd scientists believe that the breakthrough could help solve the COVID-19 pandemic by accelerating identification of the SARS-CoV-2 virus, and the scientific analysis of the effectiveness of COVID-19 therapeutics.
Scientists from Halberd believe that rapid identification is essential to permit effectively initiating therapeutics in the earliest phases of COVID-19. Early identification and treatment could substantially curtail the spread of COVID-19.
“The progress over the past month has been phenomenal and is already yielding patentable intellectual property. We foresee this as just the first of many potential patent applications to address the rapid detection, prevention, and treatment of COVID-19,” said Dr. Patricio Reyes, Chief Technical Officer of Halberd Corporation.
Related Links:
Arizona State University
Halberd Corporation
Latest COVID-19 News
- New Immunosensor Paves Way to Rapid POC Testing for COVID-19 and Emerging Infectious Diseases
- Long COVID Etiologies Found in Acute Infection Blood Samples
- Novel Device Detects COVID-19 Antibodies in Five Minutes
- CRISPR-Powered COVID-19 Test Detects SARS-CoV-2 in 30 Minutes Using Gene Scissors
- Gut Microbiome Dysbiosis Linked to COVID-19
- Novel SARS CoV-2 Rapid Antigen Test Validated for Diagnostic Accuracy
- New COVID + Flu + R.S.V. Test to Help Prepare for `Tripledemic`
- AI Takes Guesswork Out Of Lateral Flow Testing
- Fastest Ever SARS-CoV-2 Antigen Test Designed for Non-Invasive COVID-19 Testing in Any Setting
- Rapid Antigen Tests Detect Omicron, Delta SARS-CoV-2 Variants
- Health Care Professionals Showed Increased Interest in POC Technologies During Pandemic, Finds Study
- Set Up Reserve Lab Capacity Now for Faster Response to Next Pandemic, Say Researchers
- Blood Test Performed During Initial Infection Predicts Long COVID Risk
- Low-Cost COVID-19 Testing Platform Combines Sensitivity of PCR and Speed of Antigen Tests
- Finger-Prick Blood Test Identifies Immunity to COVID-19
- Quick Test Kit Determines Immunity Against COVID-19 and Its Variants